Two Sigma Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-7,269
Closed -$311K 1283
2019
Q4
$311K Sell
7,269
-2,716
-27% -$118K ﹤0.01% 1762
2019
Q3
$359K Buy
+9,985
New +$303K ﹤0.01% 1418
2017
Q4
Sell
-5,867
Closed -$221K 1703
2017
Q3
$221K Sell
5,867
-4,997
-46% -$163K 0.02% 540
2017
Q2
$303K Buy
+10,864
New +$324K 0.06% 358

Other funds holding ACAD

Two Sigma Securities's ACAD Position: Q1 2020 in Review

Two Sigma Securities sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 7,269 shares — an estimated $311K sold.

Two Sigma Securities first reported a position in ACAD in Q2 2017 and held it in 4 quarters. The position peaked at $359K in Q3 2019. 245 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

  • Two Sigma Securities reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Two Sigma Securities sold 7,269 Acadia Pharmaceuticals shares in Q1 2020, an estimated $311K.
  • Two Sigma Securities first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 4 quarters.
  • Two Sigma Securities's Acadia Pharmaceuticals position peaked at $359K in Q3 2019.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on Two Sigma Securities's 13F filing for Q1 2020, filed 15 May 2020.